The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

MPTP     1-methyl-4-phenyl-3,6- dihydro-2H-pyridine

Synonyms: CHEMBL24172, SureCN50923, M1021_ALDRICH, CCRIS 2186, AG-E-90682, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C04599


Psychiatry related information on C04599


High impact information on C04599


Chemical compound and disease context of C04599


Biological context of C04599


Anatomical context of C04599


Associations of C04599 with other chemical compounds


Gene context of C04599


Analytical, diagnostic and therapeutic context of C04599


  1. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Burns, R.S., LeWitt, P.A., Ebert, M.H., Pakkenberg, H., Kopin, I.J. N. Engl. J. Med. (1985) [Pubmed]
  2. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., Björklund, A., Lindvall, O., Langston, J.W. N. Engl. J. Med. (1992) [Pubmed]
  3. MPTP toxicity: implications for research in Parkinson's disease. Kopin, I.J., Markey, S.P. Annu. Rev. Neurosci. (1988) [Pubmed]
  4. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M., Przedborski, S. Nat. Med. (1999) [Pubmed]
  5. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Calon, F., Hadj Tahar, A., Blanchet, P.J., Morissette, M., Grondin, R., Goulet, M., Doucet, J.P., Robertson, G.S., Nestler, E., Di Paolo, T., Bédard, P.J. Trends Neurosci. (2000) [Pubmed]
  6. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Chernet, E., Perry, K.W., Nelson, D.L., Luecke, S., Phebus, L.A., Bymaster, F.P., Paul, S.M. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  7. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Klockgether, T., Turski, L., Honoré, T., Zhang, Z.M., Gash, D.M., Kurlan, R., Greenamyre, J.T. Ann. Neurol. (1991) [Pubmed]
  8. Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. Pessiglione, M., Guehl, D., Agid, Y., Hirsch, E.C., Féger, J., Tremblay, L. Brain (2003) [Pubmed]
  9. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. Calne, D.B., Zigmond, M.J. Arch. Neurol. (1991) [Pubmed]
  10. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Tillerson, J.L., Caudle, W.M., Reverón, M.E., Miller, G.W. Exp. Neurol. (2002) [Pubmed]
  11. Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., J??ger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., Simon, D.K., Bachoo, R., Spiegelman, B.M. Cell (2006) [Pubmed]
  12. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Grimsby, J., Toth, M., Chen, K., Kumazawa, T., Klaidman, L., Adams, J.D., Karoum, F., Gal, J., Shih, J.C. Nat. Genet. (1997) [Pubmed]
  13. The role of environmental toxins in the etiology of Parkinson's disease. Tanner, C.M. Trends Neurosci. (1989) [Pubmed]
  14. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases? Cole, G.M. Neuron (2003) [Pubmed]
  15. Benztropine inhibits toxicity of MPTP in mice. Bradbury, A.J., Kelly, M.E., Costall, B., Naylor, R.J., Jenner, P., Marsden, G.D. Lancet (1985) [Pubmed]
  16. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Javitch, J.A., D'Amato, R.J., Strittmatter, S.M., Snyder, S.H. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  17. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Steiner, J.P., Hamilton, G.S., Ross, D.T., Valentine, H.L., Guo, H., Connolly, M.A., Liang, S., Ramsey, C., Li, J.H., Huang, W., Howorth, P., Soni, R., Fuller, M., Sauer, H., Nowotnik, A.C., Suzdak, P.D. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  18. Parkinson's disease: mechanisms and models. Dauer, W., Przedborski, S. Neuron (2003) [Pubmed]
  19. Budipine and the MPTP binding site. Przuntek, H., Russ, H. Lancet (1985) [Pubmed]
  20. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Wu, D.C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., Przedborski, S. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  21. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Takahashi, N., Miner, L.L., Sora, I., Ujike, H., Revay, R.S., Kostic, V., Jackson-Lewis, V., Przedborski, S., Uhl, G.R. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  22. MPTP delta, a putative murine homolog of HPTP delta, is expressed in specialized regions of the brain and in the B-cell lineage. Mizuno, K., Hasegawa, K., Katagiri, T., Ogimoto, M., Ichikawa, T., Yakura, H. Mol. Cell. Biol. (1993) [Pubmed]
  23. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Bergman, H., Wichmann, T., DeLong, M.R. Science (1990) [Pubmed]
  24. Inhibition of dihydropteridine reductase by novel 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs. Abell, C.W., Shen, R.S., Gessner, W., Brossi, A. Science (1984) [Pubmed]
  25. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Luquin, M.R., Montoro, R.J., Guillén, J., Saldise, L., Insausti, R., Del Río, J., López-Barneo, J. Neuron (1999) [Pubmed]
  26. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Drouot, X., Oshino, S., Jarraya, B., Besret, L., Kishima, H., Remy, P., Dauguet, J., Lefaucheur, J.P., Dollé, F., Condé, F., Bottlaender, M., Peschanski, M., Kéravel, Y., Hantraye, P., Palfi, S. Neuron (2004) [Pubmed]
  27. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Ourednik, J., Ourednik, V., Lynch, W.P., Schachner, M., Snyder, E.Y. Nat. Biotechnol. (2002) [Pubmed]
  28. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Tomac, A., Lindqvist, E., Lin, L.F., Ogren, S.O., Young, D., Hoffer, B.J., Olson, L. Nature (1995) [Pubmed]
  29. Timing of levodopa therapy: evidence from MPTP-treated primates. Clarke, C.E., Boyce, S., Sambrook, M.A., Crossman, A.R. Lancet (1987) [Pubmed]
  30. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Frim, D.M., Uhler, T.A., Galpern, W.R., Beal, M.F., Breakefield, X.O., Isacson, O. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  31. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Ara, J., Przedborski, S., Naini, A.B., Jackson-Lewis, V., Trifiletti, R.R., Horwitz, J., Ischiropoulos, H. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  32. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Grimsby, J., Chen, K., Wang, L.J., Lan, N.C., Shih, J.C. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  33. Functional recovery in parkinsonian monkeys treated with GDNF. Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J., Gerhardt, G.A. Nature (1996) [Pubmed]
  34. Association of a monoamine oxidase B allele with Parkinson's disease. Kurth, J.H., Kurth, M.C., Poduslo, S.E., Schwankhaus, J.D. Ann. Neurol. (1993) [Pubmed]
  35. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo? Sriram, K., Benkovic, S.A., Hebert, M.A., Miller, D.B., O'Callaghan, J.P. J. Biol. Chem. (2004) [Pubmed]
  36. Effects of systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mice on tyrosine hydroxylase, L-3,4-dihydroxyphenylalanine decarboxylase, dopamine beta-hydroxylase, and monoamine oxidase activities in the striatum and hypothalamus. Mogi, M., Harada, M., Kojima, K., Kiuchi, K., Nagatsu, T. J. Neurochem. (1988) [Pubmed]
  37. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B. J. Neurochem. (2004) [Pubmed]
  38. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., Kopin, I.J. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  39. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Pate, B.D., Kawamata, T., Yamada, T., McGeer, E.G., Hewitt, K.A., Snow, B.J., Ruth, T.J., Calne, D.B. Ann. Neurol. (1993) [Pubmed]
  40. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. Palombo, E., Porrino, L.J., Bankiewicz, K.S., Crane, A.M., Sokoloff, L., Kopin, I.J. J. Neurosci. (1990) [Pubmed]
WikiGenes - Universities